3 April 2020 Novartis, in alliance with Incyte, has announced plans to assess Jakavi (ruxolitinib) in a Phase III clinical trial to treat cytokine storm in patients with severe Covid-19 pneumonia.
The planned trial will compare a combination of Jakavi and standard-of-care (SoC) therapy against SoC alone. Amgen has partnered with Adaptive Biotechnologies to discover and develop fully human neutralising antibodies targeting the SARS-CoV-2 virus that could prevent or treat Covid-19.
The alliance will combine Adaptive’s immune medicine platform with Amgen’s immunology and antibody development expertise. Read the full story here.
Vaccine development companies FluGen and Bharat Biotech have partnered with the University of Wisconsin–Madison to